HighTower Advisors LLC Has $1.79 Million Stock Holdings in Humana Inc. (NYSE:HUM)

HighTower Advisors LLC reduced its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,047 shares of the insurance provider's stock after selling 1,945 shares during the period. HighTower Advisors LLC's holdings in Humana were worth $1,788,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FPC Investment Advisory Inc. bought a new position in Humana in the 4th quarter worth $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter worth approximately $30,000. OFI Invest Asset Management bought a new stake in shares of Humana in the fourth quarter valued at approximately $33,000. Atwood & Palmer Inc. boosted its position in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after acquiring an additional 60 shares during the period. Finally, Kestra Investment Management LLC acquired a new stake in shares of Humana in the fourth quarter worth $49,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

HUM traded down $0.44 during midday trading on Thursday, hitting $270.04. The company had a trading volume of 1,284,380 shares, compared to its average volume of 1,599,551. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market capitalization of $32.59 billion, a PE ratio of 27.14, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm's 50-day simple moving average is $270.63 and its 200-day simple moving average is $274.97.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio is 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.37% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HUM. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Barclays increased their target price on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research report on Monday, January 6th. Finally, Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Eighteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.